

18. Lee, Y.R., Yuan, W.C., Ho, H.C., Chen, C.H., Shih, H.M. and Chen, R.H. (2010) The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responses. *EMBO J.*, **29**, 1748–1761.
19. Lin, M.Y., Lin, Y.M., Kao, T.C., Chuang, H.H. and Chen, R.H. (2011) PDZ-RhoGEF ubiquitination by Cullin3-KLHL20 controls neurotrophin-induced neurite outgrowth. *J. Cell Biol.*, **193**, 985–994.
20. Uchida, S., Sohara, E., Rai, T. and Sasaki, S. (2013) Regulation of with-no-lysine kinase signaling by Kelch-like proteins. *Biol. Cell*, **106**, 45–56.
21. Wakabayashi, M., Mori, T., Isobe, K., Sohara, E., Susa, K., Araki, Y., Chiga, M., Kikuchi, E., Nomura, N., Mori, Y. *et al.* (2013) Impaired KLHL3-mediated ubiquitination of WNK4 causes human hypertension. *Cell Rep.*, **3**, 858–868.
22. Wu, G. and Peng, J.B. (2013) Disease-causing mutations in KLHL3 impair its effect on WNK4 degradation. *FEBS Lett.*, **587**, 1717–1722.
23. Shibata, S., Zhang, J., Puthumana, J., Stone, K.L. and Lifton, R.P. (2013) Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4. *Proc. Natl Acad. Sci. USA*, **110**, 7838–7843.
24. Ohta, A., Schumacher, F.R., Mehellou, Y., Johnson, C., Knebel, A., Macartney, T.J., Wood, N.T., Alessi, D.R. and Kurz, T. (2013) The CUL3-KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction. *Biochem. J.*, **451**, 111–122.
25. Kim-Kaneyama, J.R., Takeda, N., Sasai, A., Miyazaki, A., Sata, M., Hirabayashi, T., Shibanauma, M., Yamada, G. and Nose, K. (2011) Hic-5 deficiency enhances mechanosensitive apoptosis and modulates vascular remodeling. *J. Mol. Cell. Cardiol.*, **50**, 77–86.
26. Mori, Y., Wakabayashi, M., Mori, T., Araki, Y., Sohara, E., Rai, T., Sasaki, S. and Uchida, S. (2013) Decrease of WNK4 ubiquitination by disease-causing mutations of KLHL3 through different molecular mechanisms. *Biochem. Biophys. Res. Commun.*, **439**, 30–34.
27. Takahashi, D., Mori, T., Wakabayashi, M., Mori, Y., Susa, K., Zeniya, M., Sohara, E., Rai, T., Sasaki, S. and Uchida, S. (2013) KLHL2 interacts with and ubiquitinates WNK kinases. *Biochem. Biophys. Res. Commun.*, **437**, 457–462.
28. Sohara, E., Rai, T., Yang, S.S., Ohta, A., Naito, S., Chiga, M., Nomura, N., Lin, S.H., Vandewalle, A., Ohta, E. *et al.* (2011) Acute insulin stimulation induces phosphorylation of the Na-Cl cotransporter in cultured distal mpkDCT cells and mouse kidney. *PLoS One*, **6**, e24277.
29. Nishida, H., Sohara, E., Nomura, N., Chiga, M., Alessi, D.R., Rai, T., Sasaki, S. and Uchida, S. (2012) Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. *Hypertension*, **60**, 981–990.
30. Chávez-Canales, M., Arroyo, J.P., Ko, B., Vázquez, N., Bautista, R., Castañeda-Bueno, M., Bobadilla, N.A., Hoover, R.S. and Gamba, G. (2013) Insulin increases the functional activity of the renal NaCl cotransporter. *J. Hypertens.*, **31**, 303–311.
31. Komers, R., Rogers, S., Oyama, T.T., Xu, B., Yang, C.L., McCormick, J. and Ellison, D.H. (2012) Enhanced phosphorylation of Na(+)-Cl(-) co-transporter in experimental metabolic syndrome: role of insulin. *Clin. Sci. (Lond.)*, **123**, 635–647.
32. Talati, G., Ohta, A., Rai, T., Sohara, E., Naito, S., Vandewalle, A., Sasaki, S. and Uchida, S. (2010) Effect of angiotensin II on the WNK-OSR1/SPAK-NCC phosphorylation cascade in cultured mpkDCT cells and in vivo mouse kidney. *Biochem. Biophys. Res. Commun.*, **393**, 844–848.
33. Zeniya, M., Sohara, E., Kita, S., Iwamoto, T., Susa, K., Mori, T., Oi, K., Chiga, M., Takahashi, D., Yang, S.S. *et al.* (2013) Dietary salt intake regulates WNK3-SPAK-NKCC1 phosphorylation cascade in mouse aorta through angiotensin II. *Hypertension*, **62**, 872–878.
34. San-Cristobal, P., Pacheco-Alvarez, D., Richardson, C., Ring, A.M., Vazquez, N., Rafiqi, F.H., Chari, D., Kahle, K.T., Leng, Q., Bobadilla, N.A. *et al.* (2009) Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway. *Proc. Natl Acad. Sci. USA*, **106**, 4384–4389.
35. Chiga, M., Rai, T., Yang, S.S., Ohta, A., Takizawa, T., Sasaki, S. and Uchida, S. (2008) Dietary salt regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride cotransporter through aldosterone. *Kidney Int.*, **74**, 1403–1409.
36. Susa, K., Sohara, E., Isobe, K., Chiga, M., Rai, T., Sasaki, S. and Uchida, S. (2012) WNK-OSR1/SPAK-NCC signal cascade has circadian rhythm dependent on aldosterone. *Biochem. Biophys. Res. Commun.*, **427**, 743–747.
37. Rozansky, D.J., Cornwall, T., Subramanya, A.R., Rogers, S., Yang, Y.F., David, L.L., Zhu, X., Yang, C.L. and Ellison, D.H. (2009) Aldosterone mediates activation of the thiazide-sensitive Na-Cl cotransporter through an SGK1 and WNK4 signaling pathway. *J. Clin. Invest.*, **119**, 2601–2612.
38. McCormick, J.A., Nelson, J.H., Yang, C.L., Curry, J.N. and Ellison, D.H. (2011) Overexpression of the sodium chloride cotransporter is not sufficient to cause familial hyperkalemic hypertension. *Hypertension*, **58**, 888–894.
39. Wang, Q., Hummler, E., Nussberger, J., Clément, S., Gabbiani, G., Brunner, H.R. and Burnier, M. (2002) Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes. *J. Am. Soc. Nephrol.*, **13**, 1509–1516.
40. Liu, P., Jenkins, N.A. and Copeland, N.G. (2003) A highly efficient recombineering-based method for generating conditional knockout mutations. *Genome Res.*, **13**, 476–484.
41. Warming, S., Costantino, N., Court, D.L., Jenkins, N.A. and Copeland, N.G. (2005) Simple and highly efficient BAC recombineering using galK selection. *Nucleic Acids Res.*, **33**, e36.
42. Sohara, E., Rai, T., Yang, S.S., Uchida, K., Nitta, K., Horita, S., Ohno, M., Harada, A., Sasaki, S. and Uchida, S. (2006) Pathogenesis and treatment of autosomal-dominant nephrogenic diabetes insipidus caused by an aquaporin 2 mutation. *Proc. Natl Acad. Sci. USA*, **103**, 14217–14222.
43. Sakai, K. and Miyazaki, J. (1997) A transgenic mouse line that retains Cre recombinase activity in mature oocytes irrespective of the cre transgene transmission. *Biochem. Biophys. Res. Commun.*, **237**, 318–324.
44. Ohta, A., Rai, T., Yui, N., Chiga, M., Yang, S.S., Lin, S.H., Sohara, E., Sasaki, S. and Uchida, S. (2009) Targeted disruption of the Wnk4 gene decreases phosphorylation of Na-Cl cotransporter, increases Na excretion and lowers blood pressure. *Hum. Mol. Genet.*, **18**, 3978–3986.
45. Wade, J.B., Fang, L., Coleman, R.A., Liu, J., Grimm, P.R., Wang, T. and Welling, P.A. (2011) Differential regulation of ROMK (Kir1.1) in distal nephron segments by dietary potassium. *Am. J. Physiol. Renal. Physiol.*, **300**, F1385–F1393.
46. Oi, K., Sohara, E., Rai, T., Misawa, M., Chiga, M., Alessi, D.R., Sasaki, S. and Uchida, S. (2012) A minor role of WNK3 in regulating phosphorylation of renal NKCC2 and NCC co-transporters in vivo. *Biol. Open*, **1**, 120–127.
47. O'Reilly, M., Marshall, E., Macgillivray, T., Mittal, M., Xue, W., Kenyon, C.J. and Brown, R.W. (2006) Dietary electrolyte-driven responses in the renal WNK kinase pathway in vivo. *J. Am. Soc. Nephrol.*, **17**, 2402–2413.



OPEN ACCESS

WNK4 is the major WNK positively regulating NCC in the mouse kidney

Daiei TAKAHASHI*, Takayasu MORI*, Naohiro NOMURA*, Muhammad Zakir Hossain KHAN*, Yuya ARAKI*, Moko ZENIYA*, Eisei SOHARA*, Tatemitsu RAI*, Sei SASAKI* and Shinichi UCHIDA*¹

*Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo 113-8519, Japan

Synopsis

By analysing the pathogenesis of a hereditary hypertensive disease, PHAII (pseudohypoaldosteronism type II), we previously discovered that WNK (with-no-lysine kinase)–OSR1/SPAK (oxidative stress-responsive 1/Ste20-like proline/alanine-rich kinase) cascade regulates NCC (Na–Cl co-transporter) in the DCT (distal convoluted tubules) of the kidney. However, the role of WNK4 in the regulation of NCC remains controversial. To address this, we generated and analysed WNK4^{-/-} mice. Although a moderate decrease in SPAK phosphorylation and a marked increase in WNK1 expression were evident in the kidneys of WNK4^{-/-} mice, the amount of phosphorylated and total NCC decreased to almost undetectable levels, indicating that WNK4 is the major WNK positively regulating NCC, and that WNK1 cannot compensate for WNK4 deficiency in the DCT. Insulin- and low-potassium diet-induced NCC phosphorylation were abolished in WNK4^{-/-} mice, establishing that both signals to NCC were mediated by WNK4. As shown previously, a high-salt diet decreases phosphorylated and total NCC in WNK4^{+/+} mice via AngII (angiotensin II) and aldosterone suppression. This was not ameliorated by WNK4 knock out, excluding the negative regulation of WNK4 on NCC postulated to be active in the absence of AngII stimulation. Thus, WNK4 is the major positive regulator of NCC in the kidneys.

Key words: angiotensin II, distal convoluted tubule, hypertension, kidney, Na–Cl co-transporter, with-no-lysine kinase (WNK).

Cite this article as: Takahashi, D., Mori, T., Nomura, N., Zakir Hossain Khan, M., Araki, Y., Zeniya, M., Sohara, E., Rai, T., Sasaki, S. and Uchida, S. (2014) WNK4 is the major WNK positively regulating NCC in the mouse kidney. *Biosci. Rep.* **34**(3), art:e00107.doi:10.1042/BSR20140047

INTRODUCTION

PHAII (pseudohypoaldosteronism type II) is a hereditary hypertensive disease characterized by hypokalaemia, metabolic acidosis and thiazide sensitivity [1]. In 2001, *WNK* (with-no-lysine kinase) 1 and *WNK4* were identified as the genes responsible for PHAII [2]. The high thiazide sensitivity of PHAII suggested that activation of the NCC (Na–Cl co-transporter) in the DCT (distal convoluted tubules) of the kidneys was responsible for its pathogenesis. Therefore, several investigations on the regulation of NCC by WNKs were performed [3,4]. Initially, some of these studies reported that wild-type WNK4 negatively regulated NCC in *Xenopus* oocytes [5,6], which was reportedly not kinase

activity-dependent function of WNK4 [7,8]. However, we generated and analysed PHAII model mice (*WNK4*^{D561A/+}) carrying a PHAII-causing mutation in WNK4, and discovered a novel signalling cascade between WNK and NCC via OSR1 (oxidative stress-responsive 1) and SPAK (Ste20-like proline/alanine-rich kinase) in the kidney [9,10]. We reported that constitutive activation of this signalling cascade caused the molecular pathogenesis of PHAII induced by WNK4 mutation [10,11]. Because both WNK1 and WNK4 were demonstrated to positively influence OSR1 and SPAK [12], this kinase activity-dependent effect of WNK4 must be acting positively on NCC in the kidneys. Thus, two opposing methods of NCC regulation by WNK4 were postulated, and the identity of the major mechanism of NCC regulation in the kidneys *in vivo* remained unclear. Previously,

Abbreviations: Akt, also called protein kinase B (PKB); AngII, angiotensin II; BAC, bacterial artificial chromosome; BP, blood pressure; DCT, distal convoluted tubule; ENaC, epithelial Na⁺ channel; ES, embryonic stem; KLHL3, Kelch-like family member 3; NCC, Na–Cl co-transporter; NKCC2, Na–K–Cl co-transporter isoform 2; OSR1, oxidative stress-responsive 1; PHAII, pseudohypoaldosteronism type II; RAA, renin–angiotensin–aldosterone; ROMK, renal outer medullary K⁺ channel; SPAK, Ste20-like proline/alanine-rich kinase; TG, transgenic; WNK, with-no-lysine kinase.

¹ To whom correspondence should be addressed (email suchida.kid@tmd.ac.jp)



Castañeda-Bueno et al. [13] reported the analysis of WNK4 knockout mice. However, this group focused on the role of WNK4 in AngII (angiotensin II)- or low-salt diet-induced activation of NCC, and did not completely investigate the controversial role of WNK4 in NCC regulation.

Mutations in two additional genes, *KLHL3* (*Kelch-like family member 3*) and *Cullin-3*, were recently reported to cause PHAII [14,15]. We clarified that WNK4 is a substrate of the KLHL3–Cullin-3 E3 ligase complex, and that the impaired ubiquitination of WNK4 protein and, subsequent, increase of WNK4 protein abundance in DCT would represent a common molecular pathogenesis of PHAII caused by mutations in *WNK4*, *KLHL3* or *Cullin-3* [16]. In fact, we demonstrated that WNK4 protein is increased in *WNK4^{D561A/+}* PHAII model mice [16]. These recent data strongly support a positive regulatory role for WNK4 in NCC regulation.

To obtain a definite conclusion regarding the physiological role of WNK4 in the kidneys, a more detailed examination of WNK4 knockout mice would be necessary. Previously, we generated hypomorphic WNK4 knockout mice, with the reduced function of WNK4, and obtained results suggesting that WNK4 acts positively on NCC in the kidneys [17]. However, a definite conclusion must be presented by analysing complete WNK4 knock out; to address this, we generated *WNK4^{-/-}* mice and examined them under various conditions. Because we had clarified that NCC is regulated by diets and some hormonal factors other than AngII, we first attempted to clarify whether NCC regulations other than that by AngII are WNK4-dependent. In addition, we investigated whether there was any evidence in the kidneys that supports a negative role of WNK4 in NCC regulation.

MATERIALS AND METHODS

Generation of WNK4 knockout mice

To generate *WNK4^{-/-}* mice, we prepared a BAC (bacterial artificial chromosome) clone bMQ42809 containing the mouse genomic *WNK4* locus. The targeting vector was then transfected into J1-6 ES (embryonic stem) cells by electroporation, as previously described [18]. After selection with 150 $\mu\text{g/ml}$ G418 and 2 μM ganciclovir, the targeted ES cell clones were selected by PCR. Chimeric male mice were bred with C57BL/6J females to produce heterozygous floxed (*WNK4^{lox/+}*) mice, and the neo cassette was then deleted by crossing the *WNK4^{lox/+}* mice with Cre recombinase-expressing TG (transgenic) mice [19]. Genotyping of the mice was performed by PCR using the sense primer F (5'-ACAAAGGCGCTATTGAGTGC-3') and the antisense primer R1 (5'-CGTCTGGGTCGGAAAGAAACT-3') to detect the flanked exon 2. Further PCR analysis was performed using the sense primer F and the antisense primer R2 (5'-CAAGAAGAGCATGGGACATC-3') to detect the upper loxP site.

Studies were performed on 12–16-week-old *WNK4^{+/+}*, *WNK4^{+/-}* and *WNK4^{-/-}* littermates. The mice were raised under a 12-h day and night cycle, and were fed a normal rodent diet and plain drinking water. This experiment was approved by the Animal Care and Use Committee of the Tokyo Medical and Dental University, Tokyo, Japan.

Blood measurements

Blood for electrolyte analysis was obtained as previously described [9]. Electrolyte levels were determined using an i-STAT® Portable Clinical Analyzer (Fuso Pharmaceutical Industries Ltd). Samples for plasma aldosterone measurement were obtained from the inferior vena cava under anaesthesia with pentobarbital. Plasma aldosterone levels were measured by SRL Clinical Laboratory Services.

Immunoblotting and immunofluorescence

Extraction of kidney protein samples, semi-quantitative immunoblotting and immunofluorescence were performed as previously described [9]. For semi-quantitative immunoblotting, we used entire kidney samples without the nuclear fraction (600 g) or the crude membrane fraction (17 000 g). The relative intensities of immunoblot bands were analysed and quantified using ImageJ (National Institutes of Health) software. The primary antibodies used in this study were as follows: rabbit anti-WNK1 (A301-516A; Bethyl Laboratories); anti-WNK4 [17]; rabbit anti-phosphorylated SPAK [20]; rabbit anti-SPAK (Cell Signaling Technology, Inc.); anti-phosphorylated OSR1/SPAK [17]; anti-OSR1 (M10; Abnova Corporation); rabbit anti-phosphorylated NCC (S71) [21]; guinea pig anti-NCC [22,23]; rabbit anti-ENaC (epithelial Na⁺ channel) α subunit (Chemicon International); rabbit anti-ENaC γ subunit (provided by M. Knepper, NIH) [24]; rabbit anti-ROMK (renal outer medullary K⁺ channel; provided by P. A. Welling and J. B. Wade, Maryland University) [25]; rabbit anti-actin (Cytoskeleton, Inc.); rabbit anti-phosphorylated NKCC2 (Na-K-Cl co-transporter isoform 2) [26]; guinea pig anti-NKCC2 (provided by K. Mutig, Department of Anatomy, Charité-Universitätsmedizin, Berlin) [27]; rabbit anti-phosphorylated serine/threonine protein kinase Akt [PKB (protein kinase B; also called Akt); Cell Signaling Technology, Inc.]; and rabbit anti-Akt (Santa Cruz Biotechnology, Inc.). ALP (alkaline phosphatase)-conjugated anti-IgG antibodies (Promega Corporation) were used as secondary antibodies and Western Blue® (Promega Corporation) was used to detect the signal.

Blood pressure (BP) measurement

We measured the systolic BP using implantable radiotelemetric devices. The equipment for conscious, freely moving laboratory animals was purchased from Data Sciences International, which included an implantable transmitter (model TA11PA-C10), a receiver (model RPC-1), a data-processing device (Data Exchange Matrix) and an APR-1 (ambient pressure reference monitor). All data were computed using an analysis program (Dataquest ART4.31).

Table 1 Blood biochemistry of Wnk4^{+/+} and Wnk4^{-/-} mice
Values are the means \pm S.E.M.

	Wnk4 WT (n = 16)	Wnk4 KO (n = 17)	P
Na (mM)	146.3 \pm 0.4	144.4 \pm 0.3	<0.05
K (mM)	4.58 \pm 0.15	4.59 \pm 0.15	0.958
Cl (mM)	113.1 \pm 0.6	109.2 \pm 0.8	<0.01
Glu (mg/dl)	206.9 \pm 8.1	203.4 \pm 7.3	0.737
pH	7.237 \pm 0.01	7.298 \pm 0.01	<0.001
PCO ₂ (mmHg)	57.0 \pm 1.8	52.8 \pm 1.6	0.084
HCO ₃ ⁻ (mM)	24.2 \pm 0.5	25.9 \pm 0.8	0.073
BE	- 3.3 \pm 0.5	- 0.6 \pm 0.9	<0.05
Hb (g/dl)	15.1 \pm 0.2	15.6 \pm 0.2	0.092

Statistical analysis

Comparisons between the two groups were performed using unpaired *t*-tests. One-way ANOVA with Tukey's *post hoc* test was used to evaluate statistical significance in the comparisons between multiple groups. *P*-values <0.05 were considered statistically significant. Data are presented as the means \pm S.E.M.

RESULTS

Generation of Wnk4^{-/-} mice

To generate Wnk4^{-/-} mice, we designed a targeting vector to delete a single exon (exon 2) of the *Wnk4* (Figure 1A). Homologous recombination was confirmed by PCR in ES cell lines, which were used to generate Wnk4^{fllox/+} mice. Next we crossed Wnk4^{fllox/+} mice with Cre recombinase-expressing TG mice. The Cre-mediated excision of exon 2 in heterozygous (Wnk4^{+/-}) mice was verified by PCR. Homozygous knockout (Wnk4^{-/-}) mice were successfully generated by crossing Wnk4^{+/-} mice (Figure 1B). Heterozygous and homozygous Wnk4 knockout mice exhibited no gross anatomic or behavioural abnormalities, and presented a normal birth rate. Absence of Wnk4 protein in Wnk4^{-/-} mice was confirmed by immunoblotting of the kidney proteins (Figure 1C).

General characteristics of Wnk4^{-/-} mice

First, we compared venous blood chemistry between Wnk4^{-/-} mice and their wild-type littermates fed with a normal diet (Table 1). Wnk4^{-/-} mice exhibited higher plasma pH and lower plasma Na⁺ and Cl⁻ than the wild-type littermates. There was no significant difference in plasma K⁺ between the two groups; this was in contrast to the findings of Castañeda-Bueno et al. [13].

Next, we analysed the effect of dietary salt intake on the BP in Wnk4^{-/-} mice. We used radiotelemetric devices to measure the BP of Wnk4^{-/-} mice and their wild-type littermates at different dietary sodium levels. Male mice were fed normal [0.9% NaCl (w/w)], high- [4% NaCl (w/w)] or low- [0.01% (w/w)] sodium

diets for 7 days. As shown in Figure 2, no significant difference was evident while they received the normal or high-sodium diets. However, on the low-salt diet, the systolic BP of Wnk4^{-/-} mice was significantly lower than that of Wnk4^{+/+} mice during the resting period (day time; 105.9 \pm 5.84 versus 84.1 \pm 8.07 mm Hg; *n* = 3; *P* < 0.05; Figure 2A).

Expression of proteins associated with the Wnk-OSR1/SPAK-NCC phosphorylation cascade

We investigated the expression of proteins associated with the Wnk-OSR1/SPAK-NCC phosphorylation cascade in the kidneys of the mice receiving a normal diet. In the Wnk4^{+/-} mice, although the level of Wnk4 protein expression in the kidneys was about half that of Wnk4^{+/+} mice, levels of SPAK, OSR1 and NCC expression were not significantly altered by this degree of reduction in Wnk4 expression. However, total NCC and NCC phosphorylated at S71 were almost completely absent in Wnk4^{-/-} mice (Figure 2C). In contrast with a previous report [13], a significant decrease in total and phosphorylated SPAK protein was evident in Wnk4^{-/-} mice, and total OSR1 was increased. Because Wnk1 and Wnk3 are known to phosphorylate OSR1/SPAK, we also examined their expression. Wnk1 expression in the kidneys was significantly increased in Wnk4^{-/-} mice. Despite this, NCC phosphorylation remained almost absent. To clarify the segment of the kidney in Wnk4^{-/-} mice with increased Wnk1 expression, we performed double immunofluorescence staining of Wnk1 and total NCC. As shown in Supplementary Figure S1 (available at <http://www.bioscirep.org/bsr/034/bsr034e107add.htm>), the DCT were dilated, cell height was decreased and staining for NCC was reduced in the Wnk4^{-/-} mice. The Wnk1 antibody used does not usually detect significant Wnk1 expression in the kidneys of Wnk4^{+/+} mice. However, increased Wnk1 expression, co-localized with NCC expression, was evident in Wnk4^{-/-} mice, suggesting that a compensatory increase in Wnk1 occurred in the DCT, but that this was insufficient to maintain NCC activity. This compensation might be caused by the increased transcription of the *Wnk1* gene and/or by the reduced degradation of Wnk1 protein. Wnk3 protein expression was not detected by immunoblotting in the kidneys of either Wnk4^{+/+} or Wnk4^{-/-} mice (results not shown), confirming that Wnk3 is not a major Wnk in the kidneys *in vivo* [28,29], even in the absence of Wnk4.

We also investigated other transporters and channels thought to be regulated by Wnk4. The levels of expression of both the full-length and cleaved forms of the α and γ subunits of ENaC were similar between Wnk4^{+/+}, Wnk4^{+/-} and Wnk4^{-/-} mice. Castañeda-Bueno et al. [13] did not present immunoblots for ENaC. However, they did perform functional assays to estimate ENaC activity, and showed that ENaC was activated to compensate for NCC inactivation resulting from Wnk4 knockout. We thought that ENaC should be activated to compensate for NCC inactivation in our Wnk4^{-/-} mice, but the magnitude of difference may be insufficient for detection by immunoblotting, possibly because the phenotype of our Wnk4^{-/-}




Figure 1 Generation of *WNK4*^{-/-} mice

(A) Targeting strategy to generate *WNK4* knockout mice. This diagram shows the targeting construct, the wild-type *WNK4* locus, and the targeted locus before and after Cre recombination. Exon 2 was flanked by two *loxP* sites. (B) Genotyping PCR after Cre recombination using primer sets flanking exon 2 (Primer F and R1) and flanking the upper *loxP* site (Primer F and R2). In the upper panel, the 280-bp band represents the mutant allele containing the remaining *loxP* site, whereas the 1.2-kb band represents the wild-type allele. In the lower panel, the 300-bp band represents the wild-type allele, whereas the smeared band represents the homozygous knockout alleles. (C) Immunoblotting of *WNK4* from the kidneys of *WNK*^{+/+} and *WNK4*^{-/-} mice. We used 40 μg of total protein per lane. The asterisk indicates non-specific bands [22].

is milder than those analysed by Castañeda-Bueno et al. [13] given their serum potassium levels. However, ROMK was significantly increased in our *WNK4*^{-/-} mice. NKCC2 expression and phosphorylation were not significantly affected by *WNK4* knockout, consistent with our previous finding that the major *WNK4* signal in the mouse kidney does not co-localize with NKCC2 [22].

Involvement of *WNK4* in low-potassium diet- and insulin-induced NCC activation

We previously identified regulators of the *WNK*-*OSR1*/*SPAK*-*NCC* signal cascade, including salt [11] and potassium intake [30], aldosterone [11], AngII [31,32] and insulin [20,33]. However, the identity of the *WNK* responsible for their regulation of *NCC* remains unclear. Low-salt diet- and




Figure 2 General characteristics of WNK4^{-/-} mice

(A) Radiotelemetric analyses of BP in WNK4^{+/+} and WNK4^{-/-} male mice receiving diets with differing salt contents. Systolic BP in WNK4^{+/+} mice remained stable in response to diets with differing salt contents. In contrast, WNK4^{-/-} mice exhibited a significantly lower BP when fed a low-salt diet (**P* < 0.05). (B) Representative radiotelemetric measurements of BP. Although WNK4^{+/+} mice were unaffected by diets with differing salt contents, WNK4^{-/-} mice exhibited lower BP when fed a low-salt diet. BP returned to normal when dietary salt reverted to normal levels. (C) Representative immunoblotting analyses of kidney proteins in WNK4^{+/+} (WT), WNK4^{+/-} (He), and WNK4^{-/-} (KO) mice fed a normal diet. The numbers reflect the results of semi-quantification by densitometry (**P* < 0.05 versus WNK4^{+/+} mice, #*P* < 0.05 versus WNK4^{+/-} mice; *n* = 5, expressed as percentages, means ± S.E.M.). We used 40 μg of total protein per lane. WNK4 in WNK4^{+/-} mice was about half that in wild-type mice, and was absent in WNK4^{-/-} mice. WNK1 increased in WNK4^{-/-} mice. Total and phosphorylated SPAK expression decreased in WNK4^{-/-} mice. Total OSR1 expression increased in WNK4^{-/-} mice. NCC expression did not decrease in WNK4^{+/-} mice, but NCC was almost completely absent in WNK4^{-/-} mice. ROMK expression increased in WNK4^{-/-} mice.




Figure 3 Responses to a low-potassium diet in $WNK4^{-/-}$ mice

(A) Immunoblots of the kidney proteins of $WNK4^{+/+}$ and $WNK4^{-/-}$ mice fed normal (open bars) or low-potassium (black bars) diets for 7 days before experiments ($*P < 0.05$; $n = 5-6$). Both $WNK4^{+/+}$ and $WNK4^{-/-}$ mice showed increased phosphorylation of SPAK when fed the low-potassium diet. However, $WNK4^{-/-}$ mice did not exhibit increased phosphorylation of NCC. (B) In $WNK4^{-/-}$ mice, WNK1 increased with a low-potassium diet (black bar) compared with a normal diet (open bar; $*P < 0.05$; $n = 5$).

AngII-induced NCC activation are reduced in $WNK4$ knock-out mice [13]. Therefore, we investigated the involvement of $WNK4$ in the regulation of NCC by a low-potassium diet and insulin.

First, we fed the mice a low-potassium diet [0.03% (w/w) KCl] for 7 days. A low-potassium diet-induced increase in total and phosphorylated NCC observed in $WNK4^{+/+}$ mice was not evident in $WNK4^{-/-}$ mice. In contrast, both $WNK4^{+/+}$ and $WNK4^{-/-}$ mice exhibited increased SPAK phosphorylation, when fed a low-potassium diet (Figure 3A). We hypothesized that other WNKs may be involved in SPAK activation in nephron

segments other than the DCT in $WNK4^{-/-}$ mice, and examined WNK1 expression in these mice. As expected, a further increase in WNK1 expression was evident in $WNK4^{-/-}$ mice fed a low-potassium diet (Figure 3B).

We then performed an acute insulin infusion experiment in $WNK4^{-/-}$ mice by administering insulin intraperitoneally at a dose of 5 U/kg, and killed the mice 60 min after injection. As shown in Figure 4, insulin-induced SPAK and NCC phosphorylation in the kidneys did not occur in $WNK4^{-/-}$ mice, indicating that the effect of insulin signalling on SPAK and NCC is exclusively mediated by $WNK4$.




Figure 4 Response to acute insulin administration in *Wnk4*^{-/-} mice. Immunoblots of kidney proteins from *Wnk4*^{+/+} and *Wnk4*^{-/-} mice infused with vehicle (open bars) or insulin (black bars). Insulin-induced SPAK and NCC phosphorylation were not observed in *Wnk4*^{-/-} mice. Insulin was administered intraperitoneally at a dose of 5 units/kg. Control mice received vehicle alone. Mice were killed 60 min after insulin injection (**P* < 0.05; *n* = 5).

Role of WNK4 in the regulation of NCC in mice fed a high-salt diet



We showed that WNK4 behaves as a positive regulator of NCC through the activation of SPAK and OSR1 in the kidneys *in vivo* [10,17]. However, some still believe that WNK4 is a negative regulator of NCC, switching to positive regulation only in the presence of AngII signalling [32]. Therefore, we investigated the role of WNK4 in NCC regulation under suppression of the RAA (renin-angiotensin-aldosterone) system affected by a high-salt diet. We fed the mice a normal [0.9% (w/w) NaCl] or high-sodium [4% (w/w) NaCl] diet for 7 days before the extraction of the kidney proteins and collection of blood samples. Aldosterone levels were significantly decreased by the high-salt diet in *Wnk4*^{+/+} and *Wnk4*^{-/-} mice (Figure 5A), indicating that the RAA system was suppressed. As shown previously [11] and in Figure 5(B), a high-salt diet suppressed phosphorylation of SPAK and NCC and reduced total NCC in *Wnk4*^{+/+} mice. If WNK4 is a negative regulator of NCC in the absence of AngII signalling in *Wnk4*^{+/+} mice, NCC should be activated by a mechanism independent of WNK-OSR1/SPAK signalling in *Wnk4* knockout mice [8]. However, phosphorylated and total NCC did not increase in *Wnk4*^{-/-} mice compared with *Wnk4*^{+/+} mice, remaining almost undetectable. Furthermore, BP in *Wnk4*^{-/-} mice did not increase compared with *Wnk4*^{+/+} mice, even with a high-salt diet (Figure 2A), suggesting that NCC is never activated in the absence of WNK4. Thus, there is no evidence for

a negative regulatory role of WNK4 in NCC regulation in the kidneys, even when RAA signalling is suppressed.

DISCUSSION

In hypertension research, the mechanism of renal sodium transport regulation is a controversial issue. In this study, we clarified the essential role of WNK4 as a positive regulator of NCC in the kidneys using the WNK4 knockout mice. We demonstrated that NCC expression and phosphorylation are highly dependent on the presence of WNK4, and that the absence of WNK4 does not promote NCC expression under any of the conditions tested in this study.

There is now general consensus that the phosphorylation status of NCC reflects its *in vivo* activity [34]. NCC phosphorylation at specific N-terminal sites was shown to be important for its transport activity [34], and also for its localization at the apical plasma membrane [9,35]. We have often observed that a decrease in NCC phosphorylation is accompanied by a decrease in total NCC in the kidneys [10,11]. We believe that the primary change was in phosphorylation because we often observed the magnitude of change in phosphorylation was greater than that in total NCC. We recently showed that phosphorylation inhibits NCC

A

B

Figure 5 Response to a high-salt diet in $WNK4^{-/-}$ mice

(A) Plasma aldosterone level in $WNK4^{+/+}$ and $WNK4^{-/-}$ mice on a normal (open bars) or high-salt (black bars) diet. There was no difference between $WNK4^{+/+}$ and $WNK4^{-/-}$ mice. A high-salt diet significantly decreased aldosterone levels in both groups ($*P < 0.05$; $n = 5-6$). (B) Immunoblots of the kidney proteins of $WNK4^{+/+}$ and $WNK4^{-/-}$ mice fed a normal (open bars) or high-salt (black bars) diet for 7 days ($*P < 0.05$; $n = 5$). $WNK4$ knock out did not ameliorate the decreased phosphorylation and total amount of Na-Cl cotransporter caused by a high-salt diet.

ubiquitination, supporting this theory [36]. In this respect, NCC regulation by phosphorylation as a result of WNK - $OSR1$ / $SPAK$ signalling is the major mechanism of NCC regulation, and $WNK4$ must be considered an important positive regulator of NCC, as both $WNK4$ and $WNK1$ were shown to phosphorylate $OSR1$ and $SPAK$ *in vitro* [12]. Furthermore, the discovery of new genes ($KLHL3$ and $Cullin-3$) responsible for PHAII [14,15] supports the notion that $WNK4$ positively regulates NCC in the human kidney. Recently, we also generated several lines of wild-type $WNK4$ -BAC TG mice, and showed that overexpression of $WNK4$ in the kidneys robustly increased $SPAK$ and NCC phosphorylation and induced PHAII phenotypes [16]. Before this study, Lalioti et al. [37] reported that a single line of $WNK4$ TG mice appeared to show inhibition, rather than activation, of the NCC function. This data was the sole *in vivo* evidence validating the negative effect of wild-type $WNK4$ on NCC suggested by *in vitro* studies [5,6].

However, Lalioti et al. data [37] should be interpreted with caution, considering the pitfalls inherent in studies using TG mice [16].

In this study, $WNK4^{-/-}$ mice exhibited an almost complete absence of total and phosphorylated NCC on immunoblots, consistent with the data of Castañeda-Bueno et al. [13]. Although this group focused on the role of $WNK4$ in NCC regulation in the presence of AngII stimulation, their analyses of $WNK4$ knock-out mice gave us further opportunity to investigate the role of $WNK4$ in NCC regulation under other conditions, thereby establishing a complete picture of the role of $WNK4$ in NCC regulation *in vivo*. As shown by our results, NCC was never up-regulated or activated by the deletion of $WNK4$ even in the absence of AngII stimulation. We are not denying the inhibitory effect of wild-type $WNK4$ on NCC observed in *Xenopus* oocytes [5,6] and cultured cells [38]. However, these inhibitory effects may

be minimal in the kidneys *in vivo*, overwhelmed by the strong positive regulation of NCC by Wnk4 via its phosphorylation. The importance of phosphorylation to the regulation of NCC is confirmed by the absence of PHAII phenotypes in NCC TG mice [39]. An increase in the abundance of NCC alone, without upstream Wnk–OSR1/SPAK signalling, does not result in NCC activation.

We observed some minor phenotypic differences between our Wnk4^{-/-} mice and those used by Castañeda-Bueno et al. [13]. Wnk4 knockout mice used by Castañeda-Bueno et al. [13] exhibited hypokalaemia, but our Wnk4^{-/-} mice did not exhibit hypokalaemia. We observed a slight but significant decrease in total and phosphorylated SPAK in our Wnk4^{-/-} mice, and an increase in total OSR1, but those used by Castañeda-Bueno et al. [13] did not exhibit any significant changes in SPAK and OSR1. The origin of these disparities is unclear, but differences in genetic background may provide one explanation, as both Wnk4 knockout mice have a mixed background (C57BL/6J and 129Sv), and the contribution of these strains to each Wnk4 knockout mouse may differ. Regarding serum potassium, even NCC knockout mice did not exhibit hypokalaemia [40], suggesting that normokalaemia in our Wnk4^{-/-} mice is not necessarily unexpected. It is also true that data on serum potassium in mice vary significantly depending on how blood samples are collected (after killing versus alive but under anaesthesia). As for the differences in SPAK and OSR1, these may originate from the antibodies used in the two studies.

We also obtained data on Wnk-related molecules not described in the study by Castañeda-Bueno et al. [13]. We demonstrated that Wnk1, but not Wnk3, underwent a compensatory increase in Wnk4^{-/-} mice, further establishing the minor involvement of Wnk3 in NCC regulation in the kidneys. However, this increase in Wnk1 in the DCT may be insufficient to compensate for Wnk4 deletion, as NCC phosphorylation was significantly decreased in Wnk4^{-/-} mice. Although insufficient to compensate for the absence of Wnk4, this finding suggests that Wnk1 has the same role as Wnk4 in the DCT. As no controversy surrounds the positive influence of Wnk1 on NCC, this data also supports the positive role of Wnk4 in NCC regulation. An increase in Wnk1 expression was also evident in Wnk4^{-/-} mice fed a low-potassium diet (Figure 3B). Increased Wnk1 expression may explain the increase in SPAK phosphorylation, but did not contribute to NCC phosphorylation, suggesting that the increased phosphorylation of SPAK in Wnk4^{-/-} mice fed a low-potassium diet occurs in nephron segments other than the DCT.

For the first time, we have presented the status of ROMK in Wnk4^{-/-} mice. Previously, ROMK was shown to be inhibited by wild-type Wnk4, and strongly inhibited by PHAII-causing mutant Wnk4 [41]. Through the analysis of Wnk4^{D561A/+} PHAII model mice crossed with *Osr1* and *Spak* knock-in mice, we showed that the pathogenesis of hypokalaemia is also the result of NCC activation by Wnk–OSR1/SPAK signalling, but is not caused by a direct effect of mutant Wnk4 on ROMK. However, the effect of wild-type Wnk4 on ROMK has not been clarified *in vivo*. We observed a clear increase in ROMK in the

immunoblots of the total kidney samples from Wnk4^{-/-} mice exhibiting normal serum potassium levels. Although further detailed analyses focusing on intracellular localization are necessary, our data suggest that wild-type Wnk4 behaves as a negative regulator of ROMK in the kidneys, consistent with *in vitro* studies [41].

In conclusion, data obtained from our Wnk4^{-/-} mice under various conditions clearly show that Wnk4 is a strong positive regulator, and never a negative regulator, of NCC in the mouse kidney *in vivo*.

AUTHOR CONTRIBUTIONS

Daiei Takahashi performed the mice studies, and wrote the manuscript. Takayasu Mori, Naohiro Nomura, Muhammad Zankir Hossain Khan, Eisei Sohara and Tatemitsu Rai generated Wnk4^{-/-} mice. Yuya Araki, Moko Zeniya and Sei Sasaki helped in general experimental procedures and contributed to data discussion. Shinichi Uchida designed and directed the project and wrote the manuscript.

FUNDING

This work was supported in part by Grants-in-Aid for Scientific Research (S) from the Japan Society for the Promotion of Science, a Health Labor Science Research Grant from the Ministry of Health Labor and Welfare, Salt Science Research Foundation [grant numbers 1026, 1228], and the Takeda Science Foundation.

REFERENCES

- Gordon, R. D. (1986) The syndrome of hypertension and hyperkalemia with normal glomerular filtration rate: Gordon's syndrome. *Aust. N. Z. J. Med.* **16**, 183–184 [CrossRef PubMed](#)
- Wilson, F. H., Disse-Nicodème, S., Choate, K. A., Ishikawa, K., Nelson-Williams, C., Desitter, I., Gunel, M., Milford, D. V., Lipkin, G. W., Achard, J. M. et al. (2001) Human hypertension caused by mutations in Wnk kinases. *Science* **293**, 1107–1112 [CrossRef PubMed](#)
- Richardson, C. and Alessi, D. R. (2008) The regulation of salt transport and blood pressure by the Wnk–SPAK/OSR1 signalling pathway. *J. Cell. Sci.* **121**, 3293–3304 [CrossRef PubMed](#)
- McCormick, J. A. and Ellison, D. H. (2011) The Wnks: atypical protein kinases with pleiotropic actions. *Physiol. Rev.* **91**, 177–219 [CrossRef PubMed](#)
- Wilson, F. H., Kahle, K. T., Sabath, E., Lalioti, M. D., Rapson, A. K., Hoover, R. S., Hebert, S. C., Gamba, G. and Lifton, R. P. (2003) Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na–Cl cotransporter is inhibited by wild-type but not mutant Wnk4. *Proc. Natl. Acad. Sci. USA.* **100**, 680–684 [CrossRef](#)
- Yang, C. L., Angell, J., Mitchell, R. and Ellison, D. H. (2003) Wnk kinases regulate thiazide-sensitive Na–Cl cotransport. *J. Clin. Invest.* **111**, 1039–1045 [CrossRef PubMed](#)
- Yang, C. L., Zhu, X. and Ellison, D. H. (2007) The thiazide-sensitive Na–Cl cotransporter is regulated by a Wnk kinase signaling complex. *J. Clin. Invest.* **117**, 3403–3411 [CrossRef PubMed](#)



- 8 Yang, C. L., Zhu, X., Wang, Z., Subramanya, A. R. and Ellison, D. H. (2005) Mechanisms of WNK1 and WNK4 interaction in the regulation of thiazide-sensitive NaCl cotransport. *J. Clin. Invest.* **115**, 1379–1387 [CrossRef](#) [PubMed](#)
- 9 Yang, S. S., Morimoto, T., Rai, T., Chiga, M., Sohara, E., Ohno, M., Uchida, K., Lin, S. H., Moriguchi, T., Shibuya, H. et al. (2007) Molecular pathogenesis of pseudohypoaldosteronism type II: generation and analysis of a Wnk4(D561A/+) knockin mouse model. *Cell Metab.* **5**, 331–344 [CrossRef](#) [PubMed](#)
- 10 Chiga, M., Rafiqi, F. H., Alessi, D. R., Sohara, E., Ohta, A., Rai, T., Sasaki, S. and Uchida, S. (2011) Phenotypes of pseudohypoaldosteronism type II caused by the WNK4 D561A missense mutation are dependent on the WNK-OSR1/SPAK kinase cascade. *J. Cell. Sci.* **124**, 1391–1395 [CrossRef](#) [PubMed](#)
- 11 Chiga, M., Rai, T., Yang, S. S., Ohta, A., Takizawa, T., Sasaki, S. and Uchida, S. (2008) Dietary salt regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride cotransporter through aldosterone. *Kidney Int.* **74**, 1403–1409 [CrossRef](#) [PubMed](#)
- 12 Moriguchi, T., Urushiyama, S., Hisamoto, N., Iemura, S., Uchida, S., Natsume, T., Matsumoto, K. and Shibuya, H. (2005) WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters via the STE20-related kinases, SPAK and OSR1. *J. Biol. Chem.* **280**, 42685–42693 [CrossRef](#) [PubMed](#)
- 13 Castañeda-Bueno, M., Cervantes-Pérez, L. G., Vázquez, N., Uribe, N., Kantesaria, S., Morla, L., Bobadilla, N. A., Doucet, A., Alessi, D. R. and Gamba, G. (2012) Activation of the renal Na⁺:Cl⁻ cotransporter by angiotensin II is a WNK4-dependent process. *Proc. Natl. Acad. Sci. USA.* **109**, 7929–7934 [CrossRef](#)
- 14 Boyden, L. M., Choi, M., Choate, K. A., Nelson-Williams, C. J., Farhi, A., Toka, H. R., Tikhonova, I. R., Bjornson, R., Mane, S. M., Colussi, G. et al. (2012) Mutations in Kelch-like 3 and Cullin 3 cause hypertension and electrolyte abnormalities. *Nature* **482**, 98–102 [CrossRef](#) [PubMed](#)
- 15 Louis-Dit-Picard, H., Barc, J., Trujillano, D., Miserey-Lenkei, S., Bouatia-Naji, N., Pylypenko, O., Beaurain, G., Bonnefond, A., Sand, O., Simian, C. et al. (2012) KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. *Nat. Genet.* **44**, 456–460, S451–S453 [CrossRef](#) [PubMed](#)
- 16 Wakabayashi, M., Mori, T., Isobe, K., Sohara, E., Susa, K., Araki, Y., Chiga, M., Kikuchi, E., Nomura, N., Mori, Y. et al. (2013) Impaired KLHL3-mediated ubiquitination of WNK4 causes human hypertension. *Cell Rep.* **3**, 858–868 [CrossRef](#) [PubMed](#)
- 17 Ohta, A., Rai, T., Yui, N., Chiga, M., Yang, S. S., Lin, S. H., Sohara, E., Sasaki, S. and Uchida, S. (2009) Targeted disruption of the Wnk4 gene decreases phosphorylation of Na–Cl cotransporter, increases Na excretion and lowers blood pressure. *Hum. Mol. Genet.* **18**, 3978–3986 [CrossRef](#) [PubMed](#)
- 18 Sohara, E., Rai, T., Yang, S. S., Uchida, K., Nitta, K., Horita, S., Ohno, M., Harada, A., Sasaki, S. and Uchida, S. (2006) Pathogenesis and treatment of autosomal-dominant nephrogenic diabetes insipidus caused by an aquaporin 2 mutation. *Proc. Natl. Acad. Sci. USA.* **103**, 14217–14222 [CrossRef](#)
- 19 Sakai, K. and Miyazaki, J. (1997) A transgenic mouse line that retains Cre recombinase activity in mature oocytes irrespective of the Cre transgene transmission. *Biochem. Biophys. Res. Commun.* **237**, 318–324 [CrossRef](#) [PubMed](#)
- 20 Sohara, E., Rai, T., Yang, S. S., Ohta, A., Naito, S., Chiga, M., Nomura, N., Lin, S. H., Vandewalle, A., Ohta, E. et al. (2011) Acute insulin stimulation induces phosphorylation of the Na–Cl cotransporter in cultured distal mpkDCT cells and mouse kidney. *PLoS ONE.* **6**, e24277 [CrossRef](#) [PubMed](#)
- 21 Sandberg, M. B., Riquier, A. D., Pihakaski-Maunsbach, K., McDonough, A. A. and Maunsbach, A. B. (2007) Ang II provokes acute trafficking of distal tubule Na⁺-Cl⁻ cotransporter to apical membrane. *Am. J. Physiol. Renal Physiol.* **293**, F662–F669 [CrossRef](#) [PubMed](#)
- 22 Ohno, M., Uchida, K., Ohashi, T., Nitta, K., Ohta, A., Chiga, M., Sasaki, S. and Uchida, S. (2011) Immunolocalization of WNK4 in mouse kidney. *Histochem. Cell Biol.* **136**, 25–35 [CrossRef](#) [PubMed](#)
- 23 Isobe, K., Mori, T., Asano, T., Kawaguchi, H., Nonoyama, S., Kumagai, N., Kamada, F., Morimoto, T., Hayashi, M., Sohara, E. et al. (2013) Development of enzyme-linked immunosorbent assays for urinary thiazide-sensitive Na–Cl cotransporter measurement. *Am. J. Physiol. Renal Physiol.* **305**, F1374–1381 [CrossRef](#) [PubMed](#)
- 24 Nielsen, J., Kwon, T. H., Frøkiaer, J., Knepper, M. A. and Nielsen, S. (2007) Maintained ENaC trafficking in aldosterone-infused rats during mineralocorticoid and glucocorticoid receptor blockade. *Am. J. Physiol. Renal Physiol.* **292**, F382–F394 [CrossRef](#) [PubMed](#)
- 25 Wade, J. B., Fang, L., Coleman, R. A., Liu, J., Grimm, P. R., Wang, T. and Welling, P. A. (2011) Differential regulation of ROMK (Kir1.1) in distal nephron segments by dietary potassium. *Am. J. Physiol. Renal Physiol.* **300**, F1385–F1393 [CrossRef](#) [PubMed](#)
- 26 Yang, S. S., Lo, Y. F., Wu, C. C., Lin, S. W., Yeh, C. J., Chu, P., Sytwu, H. K., Uchida, S., Sasaki, S. and Lin, S. H. (2010) SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction. *J. Am. Soc. Nephrol.* **21**, 1868–1877 [CrossRef](#) [PubMed](#)
- 27 Mutig, K., Paliege, A., Kahl, T., Jöns, T., Müller-Esterl, W. and Bachmann, S. (2007) Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL. *Am. J. Physiol. Renal Physiol.* **293**, F1166–F1177 [CrossRef](#) [PubMed](#)
- 28 Oi, K., Sohara, E., Rai, T., Misawa, M., Chiga, M., Alessi, D. R., Sasaki, S. and Uchida, S. (2012) A minor role of WNK3 in regulating phosphorylation of renal NKCC2 and NCC co-transporters *in vivo*. *Biol. Open* **1**, 120–127 [CrossRef](#) [PubMed](#)
- 29 Mederle, K., Mutig, K., Paliege, A., Carota, I., Bachmann, S., Castrop, H. and Oppermann, M. (2013) Loss of WNK3 is compensated for by the WNK1/SPAK axis in the kidney of the mouse. *Am. J. Physiol. Renal Physiol.* **304**, F1198–1209 [CrossRef](#) [PubMed](#)
- 30 Vallon, V., Schroth, J., Lang, F., Kuhl, D. and Uchida, S. (2009) Expression and phosphorylation of the Na⁺-Cl⁻ cotransporter NCC *in vivo* is regulated by dietary salt, potassium, and SGK1. *Am. J. Physiol. Renal Physiol.* **297**, F704–F712 [CrossRef](#) [PubMed](#)
- 31 Talati, G., Ohta, A., Rai, T., Sohara, E., Naito, S., Vandewalle, A., Sasaki, S. and Uchida, S. (2010) Effect of angiotensin II on the WNK-OSR1/SPAK-NCC phosphorylation cascade in cultured mpkDCT cells and *in vivo* mouse kidney. *Biochem. Biophys. Res. Commun.* **393**, 844–848 [CrossRef](#) [PubMed](#)
- 32 San-Cristobal, P., Pacheco-Alvarez, D., Richardson, C., Ring, A. M., Vazquez, N., Rafiqi, F. H., Chari, D., Kahle, K. T., Leng, Q., Bobadilla, N. A. et al. (2009) Angiotensin II signaling increases activity of the renal Na–Cl cotransporter through a WNK4–SPAK-dependent pathway. *Proc. Natl. Acad. Sci. USA.* **106**, 4384–4389 [CrossRef](#)
- 33 Nishida, H., Sohara, E., Nomura, N., Chiga, M., Alessi, D. R., Rai, T., Sasaki, S. and Uchida, S. (2012) Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. *Hypertension* **60**, 981–990 [CrossRef](#) [PubMed](#)
- 34 Pacheco-Alvarez, D., Cristóbal, P. S., Meade, P., Moreno, E., Vazquez, N., Muñoz, E., Díaz, A., Juárez, M. E., Giménez, I. and Gamba, G. (2006) The Na⁺-Cl⁻ cotransporter is activated and phosphorylated at the amino-terminal domain upon intracellular chloride depletion. *J. Biol. Chem.* **281**, 28755–28763 [CrossRef](#) [PubMed](#)
- 35 Lee, D. H., Maunsbach, A. B., Riquier-Brison, A. D., Nguyen, M. T., Fenton, R. A., Bachmann, S., Yu, A. S. and McDonough, A. A. (2013) Effects of ACE inhibition and ANG II stimulation on renal Na–Cl cotransporter distribution, phosphorylation, and membrane complex properties. *Am. J. Physiol. Cell Physiol.* **304**, C147–C163 [CrossRef](#) [PubMed](#)

- 36 Hossain Khan, M. Z., Sohara, E., Ohta, A., Chiga, M., Inoue, Y., Isobe, K., Wakabayashi, M., Oi, K., Rai, T., Sasaki, S. and Uchida, S. (2012) Phosphorylation of Na-Cl cotransporter by OSR1 and SPAK kinases regulates its ubiquitination. *Biochem. Biophys. Res. Commun.* **425**, 456–461 [CrossRef](#) [PubMed](#)
- 37 Lalioti, M. D., Zhang, J., Volkman, H. M., Kahle, K. T., Hoffmann, K. E., Toka, H. R., Nelson-Williams, C., Ellison, D. H., Flavell, R., Booth, C. J. et al. (2006) Wnk4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. *Nat. Genet.* **38**, 1124–1132 [CrossRef](#) [PubMed](#)
- 38 Cai, H., Cebotaru, V., Wang, Y. H., Zhang, X. M., Cebotaru, L., Guggino, S. E. and Guggino, W. B. (2006) Wnk4 kinase regulates surface expression of the human sodium chloride cotransporter in mammalian cells. *Kidney Int.* **69**, 2162–2170 [CrossRef](#) [PubMed](#)
- 39 McCormick, J. A., Nelson, J. H., Yang, C. L., Curry, J. N. and Ellison, D. H. (2011) Overexpression of the sodium chloride cotransporter is not sufficient to cause familial hyperkalemic hypertension. *Hypertension* **58**, 888–894 [CrossRef](#) [PubMed](#)
- 40 Schultheis, P. J., Lorenz, J. N., Meneton, P., Nieman, M. L., Riddle, T. M., Flagella, M., Duffy, J. J., Doetschman, T., Miller, M. L. and Shull, G. E. (1998) Phenotype resembling Gitelman's syndrome in mice lacking the apical Na⁺-Cl⁻ cotransporter of the distal convoluted tubule. *J. Biol. Chem.* **273**, 29150–29155 [CrossRef](#) [PubMed](#)
- 41 Kahle, K. T., Wilson, F. H., Leng, Q., Lalioti, M. D., O'Connell, A. D., Dong, K., Rapson, A. K., MacGregor, G. G., Giebisch, G., Hebert, S. C. and Lifton, R. P. (2003) Wnk4 regulates the balance between renal NaCl reabsorption and K⁺ secretion. *Nat. Genet.* **35**, 372–376 [CrossRef](#) [PubMed](#)

Received 6 March 2014/19 March 2014; accepted 21 March 2014

Published as Immediate Publication 21 March 2014, doi 10.1042/BSR20140047



OPEN ACCESS

SUPPLEMENTARY DATA

WNK4 is the major WNK positively regulating NCC in the mouse kidney

Daiei TAKAHASHI*, Takayasu MORI*, Naohiro NOMURA*, Muhammad Zakir Hossain KHAN*, Yuya ARAKI*, Moko ZENIYA*, Eisei SOHARA*, Tatemitsu RAI*, Sei SASAKI* and Shinichi UCHIDA*¹

*Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo 113-8519, Japan




Figure S1 Immunofluorescence of WNK1 and NCC in the kidney

The immunofluorescence of WNK1 and NCC in the kidneys of WNK4^{+/+} and WNK4^{-/-} mice. An apparent increase in WNK1 in the kidneys of WNK4^{-/-} mice was only observed in the distal convoluted tubules (DCT). However, the DCT appeared to be dilated with a reduced cell height and NCC immunofluorescence.

Received 6 March 2014/19 March 2014; accepted 21 March 2014

Published as Immediate Publication 21 March 2014, doi 10.1042/BSR20140047

¹ To whom correspondence should be addressed (email suchida.kid@tmd.ac.jp)

Regulation of with-no-lysine kinase signaling by Kelch-like proteins

Shinichi Uchida¹, Eisei Sohara, Tatemitsu Rai and Sei Sasaki

Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan

In 2001, with-no-lysine (WNK) kinases were identified as the genes responsible for the human hereditary hypertensive disease pseudohypoaldosteronism type II (PHAII). It took a further 6 years to clarify that WNK kinases participate in a signaling cascade with oxidative stress-responsive gene 1 (OSR1), Ste20-related proline-alanine-rich kinase (SPAK), and thiazide-sensitive NaCl cotransporter (NCC) in the kidney and the constitutive activation of this signaling cascade is the molecular basis of PHAII. Since this discovery, the WNK–OSR1/SPAK–NCC signaling cascade has been shown to be involved not only in PHAII but also in the regulation of blood pressure under normal and pathogenic conditions, such as hyperinsulinemia. However, the molecular mechanisms of WNK kinase regulation by dietary and hormonal factors and by PHAII-causing mutations remain poorly understood. In 2012, two additional genes responsible for PHAII, *Kelch-like 3* (*KLHL3*) and *Cullin3*, were identified. At the time of their discovery, the molecular mechanisms underlying the interaction between these genes and their involvement in PHAII were unknown. Here we review the pathophysiological roles of the WNK signaling cascade clarified to date and introduce a new mechanism of WNK kinase regulation by *KLHL3* and *Cullin3*, which provides insight on previously unknown mechanisms of WNK kinase regulation.

With-no-lysine kinases and pseudohypoaldosteronism type II

Polymerase chain reaction (PCR)-based homology cloning of mitogen-activated protein kinases (MAP) and MEK kinase initially identified WNK1 kinase (Xu et al., 2000). Subsequently, a database search revealed the existence of homologous kinase genes in mammals and in other species: four homologues (*WNK1–4*) were discovered in mammals, one in *Drosophila melanogaster*, one in *Caenorhabditis elegans*, and eight in *Arabidopsis thaliana*, but none was discovered in yeast (Verissimo and Jordan, 2001). The kinases were named “with-no-lysine” (WNK) kinases because the lysine (K) residue present in subdomain II of most kinases was not conserved in WNK kinases but instead replaced with a cysteine residue. As shown in Fig. 1, a kinase domain exists at the N-terminus of WNK kinases, followed by an autoinhibitory domain (Xu et al., 2002) and a coiled-coil

domain. Another coiled-coil domain is present at the C-terminus.

In 2001, *WNK1* and *WNK4* were identified as the genes responsible for the autosomal dominant hereditary hypertensive disease pseudohypoaldosteronism type II (PHAII; Wilson et al., 2001). In addition to hypertension, PHAII is characterised by hyperkalemia, metabolic acidosis and thiazide sensitivity (Gordon, 1986). Thiazide is widely used as an anti-hypertensive drug: It induces salt excretion into the urine as it is a specific inhibitor for NaCl cotransporter (NCC) in the distal tubules of the kidney. NCC is responsible for the reabsorption of approximately 5%–10% of filtered NaCl in the glomeruli. At the time of this discovery, a substrate for WNK kinases was yet to be identified, but it was expected that NCC was regulated by *WNK1* and *WNK4* because the activation of NCC was considered the major pathogenesis of PHAII.

The mutations found in the *WNK1* gene comprised large deletions in intron 1, which were considered


¹To whom correspondence should be addressed (email: suchida.kid@tmd.ac.jp)

Key words: Hypertension, Kidney, Kinases, Membrane transport, Ubiquitin.
Abbreviations: KLHL3, Kelch-like 3; NCC, NaCl cotransporter; OSR1, oxidative stress-responsive gene 1; PHAII, pseudohypoaldosteronism type II; SPAK, Ste20-related proline-alanine rich kinase; WNK, with-no-lysine.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Figure 1 | Structures of WNK, OSR1, and SPAK kinases

Acidic domains are located downstream of the first coiled-coil domain and conserved in all WNK kinases. Three of four pseudohypoaldosteronism type II-causing mutations in *WNK4* are located in the acidic domain. WNK kinases activate OSR1 and SPAK by phosphorylating threonine residues in their kinase domains (T185 and T233). Serine residues (S325 in OSR1 and S373 in SPAK) in the S motif are also phosphorylated by WNK kinases, but their phosphorylation is not involved in the activation of the kinases. Conserved C-terminal domains in OSR1 and SPAK (shown in yellow) bind to the RFx[V/I] motif in WNK and solute carrier family 12 transporters. The N-terminal regions of NCC, NKCC1, and NKCC2 around the sites phosphorylated by OSR1 and SPAK are highly conserved.



to increase its transcription based on reverse transcription PCR analysis of *WNK1* mRNA levels in the leukocytes of patients with PHAII (Wilson et al., 2001). However, after the initial report, the existence of two isoforms in *WNK1*, full-length *WNK1* and a kidney-specific *WNK1* lacking the kinase domain, was clarified (Delaloy et al., 2003; O'Reilly et al., 2003). Exactly which isoform is increased in patients with PHAII, and whether *WNK1* expression is indeed increased in the human kidney, remains undetermined (Delaloy et al., 2008). In the case of *WNK4*, four missense mutations were identified in patients with PHAII, three of which are clustered within a distance of four amino acids in a region termed the "acidic domain" (Wilson et al., 2001). As shown in Fig. 1, this domain is well conserved in all WNK kinase isoforms.

Discovery of the WNK–oxidative stress-responsive gene 1/Ste20-related proline–alanine-rich kinase–solute carrier family 12a transporter signaling cascade

After the identification of *WNK1* and *WNK4* as the genes underlying PHAII, numerous investigations of the effects of coexpressing *WNK1* and *WNK4* with transporters, including NCC, were published (Kahle et al., 2003; Wilson et al., 2003; Yang et al., 2003; Kahle et al., 2004; Yamauchi et al., 2004, 2005; Cai et al., 2006; Gamba, 2006; Garzon-Muvdi et al., 2007; Ring et al., 2007; Yang et al., 2007a). In most studies, *WNK4* was demonstrated to exert an inhibitory effect on the transporters. However, the detailed mechanisms of this regulation, in particular the intracellular signaling cascades involved, were poorly understood. Then, in 2005, two groups

identified that oxidative stress-responsive gene 1 (OSR1) and Ste20-related proline-alanine-rich kinase (SPAK) were substrates of WNK1 and WNK4 (Moriguchi et al., 2005; Vitari et al., 2005). OSR1 and SPAK are related serine–threonine kinases that possess an N-terminal catalytic domain similar to those of other members of the Ste20 kinase subfamily, and two conserved regions known as the serine motif (S motif) and conserved C-terminal (CCT) domain. SPAK also possesses a unique 48-amino-acid N-terminal extension that primarily consists of alanine and proline. The CCT domains of OSR1 and SPAK were shown to interact with the Rfv[V/I] motif in WNK kinases and solute carrier family 12 (SLC12) transporters (Fig. 1). OSR1 and SPAK were already identified as regulators of the SLC12A2 [also known as Na-K-2Cl-cotransporter 1 (NKCC1)] cotransporter (Flemmer et al., 2002; Piechotta et al., 2002; Dowd and Forbush, 2003; Piechotta et al., 2003): through *in vitro* experiments, Moriguchi et al. (2005) demonstrated that SLC12A3 (also known as NCC) and SLC12A1 [also known as Na-K-2Cl-cotransporter 2 (NKCC2)], which belong to the same transporter family as NKCC1, could also be substrates of OSR1 and SPAK. To prove this notion in the kidney *in vivo*, Yang et al. (2007c) generated anti-phosphorylated NCC (pNCC) antibodies that recognised potential serine and threonine phosphorylation sites deduced from sequence alignment with NKCC1. They also generated a mouse model of PHAII: a knock-in mouse carrying a PHAII-causing missense mutation of *WNK4* (D561A), corresponding to the D574A mutation in patients with PHAII (Yang et al., 2007c). *Wnk4*^{D561A/+} mice exhibited a PHAII phenotype, including increased thiazide sensitivity, indicating that NCC is activated in the kidneys of the mutant mice. Using anti-pNCC antibodies, Yang et al. (2007c) demonstrated that NCC phosphorylation at three sites (Thr53, Thr58 and Ser71 in mouse NCC) was significantly increased in the kidneys of PHAII model mice, and that pNCC was concentrated on the apical plasma membranes of the distal convoluted tubules. Phosphorylation of SPAK and OSR1 was also increased in *Wnk4*^{D561A/+} mice, suggesting that WNK–OSR1/SPAK–NCC signaling was present in the kidney and activated by the PHAII-causing *WNK4* mutation. Subsequently, by crossing *Wnk4*^{D561A/+} mice with *SPAK* and *OSR1* knock-in mice, in which the T-loop Thr residues in

SPAK (Thr243) and OSR1 (Thr185) were mutated to Ala to prevent activation by WNK kinases, Chiga et al. (2011) demonstrated that NCC phosphorylation and PHAII phenotypes in *Wnk4*^{D561A/+} mice were dependent on WNK–OSR1/SPAK signaling. Thus, the WNK–OSR1/SPAK–NCC signaling cascade in the kidney was established, and its activation was shown to be the pathogenic mechanism underlying PHAII. The WNK kinase responsible for NCC phosphorylation in the kidney was later identified as WNK4 through the analysis of *WNK1*, *WNK3* and *WNK4* knockout mice (Ohta et al., 2009; Oi et al., 2012; Castaneda-Bueno et al., 2012; Susa et al., 2012).


The mechanism of NCC activation by phosphorylation was initially investigated by Pacheco-Alvarez et al. (2006) using the *Xenopus laevis* oocyte expression system. Phosphorylation-incompetent mutant NCC molecules were present on the plasma membrane, but their transport activity was significantly decreased, suggesting that phosphorylation of NCC is important for its transport activity. As previously mentioned, analysis of NCC phosphorylation in the kidney *in vivo* clarified that phosphorylated NCC was exclusively present on the apical plasma membranes of the distal convoluted tubules (Yang et al., 2007c; Pedersen et al., 2010; Lee et al., 2013), suggesting that phosphorylation regulates the plasma membrane expression of NCC. Hossain Kahn et al. (2012) found that phosphorylation of NCC decreased its ubiquitination: decreased endocytosis and/or degradation may underlie the increased phosphorylated NCC accumulation evident in the apical plasma membranes of the distal convoluted tubules.

Regulators of WNK signaling

After the discovery of the WNK–OSR1/SPAK–NCC signaling cascade in the kidney and its involvement in PHAII, its pathophysiological roles outside of PHAII were investigated (Fig. 2). Salt intake regulates this cascade, partly through aldosterone (Chiga et al., 2008; Vallon et al., 2009). High and low salt intake decreased and increased the phosphorylation of OSR1/SPAK and NCC in the kidney, respectively, adjusting the excretion of NaCl according to its intake. This regulation was abolished in *Wnk4*^{D561A/+} mice (Chiga et al., 2008): A high-salt diet did not down-regulate WNK–OSR1/SPAK–NCC signaling

Figure 2 | Regulators and effectors of WNK–OSR1/SPAK kinase signaling

NaCl and K intakes regulate WNK kinase–OSR1/SPAK–NCC signaling in the kidney. Angiotensin II, aldosterone, vasopressin, and insulin also regulate WNK–OSR1/SPAK–NCC signaling in the kidney. A WNK1/WNK3–SPAK–Na–K–2Cl–cotransporter 1 cascade regulates arterial tonus.



in PHAII model mice. Elucidation of the mechanism of this dysregulation was one of the important unanswered questions in the molecular pathogenesis of PHAII. Potassium intake also regulates this cascade; high and low potassium intake decreased and increased WNK–OSR1/SPAK–NCC signaling, respectively (Vallon et al., 2009; Sorensen et al., 2013; van der Lubbe et al., 2013). As the initial phenotype of PHAII is hyperkalemia rather than hypertension, WNK–OSR1/SPAK–NCC signaling must also regulate potassium homeostasis in the body. In this regard, it is reasonable to predict that this signaling cascade is regulated by potassium intake. Although Naito et al. (2011) reported that extracellular potassium levels directly regulated WNK1 activity in cultured cells; the mechanisms of WNK kinase regulation by dietary potassium remain unclear. Hormonal factors also regulate WNK signaling. In addition to aldosterone, angiotensin II (San-Cristobal et al., 2009; Talati et al., 2010; van der Lubbe et al., 2011; Castaneda-Bueno et al., 2012; Castaneda-Bueno and Gamba, 2012) and vasopressin (Mutig et al., 2010; Pedersen et al., 2010; Rieg et al., 2013; Saritas et al., 2013) reportedly acti-

vated this signaling cascade. However, the details of intracellular signaling from these hormones to WNK kinases are poorly understood. Recently, insulin was identified as a powerful activator of this signaling cascade, and the phosphatidylinositol 3-kinase/Akt pathway was shown to mediate the signal from insulin to WNK4 (Sohara et al., 2011; Nishida et al., 2012; Chavez-Canales et al., 2013). Constitutive activation of this cascade caused by hyperinsulinemia may underlie the pathogenesis of salt-sensitive hypertension in metabolic syndrome (Nishida et al., 2012; Komers et al., 2012).

Extrarenal roles of WNK–OSR1/SPAK kinase signaling

In addition to NaCl and K homeostasis in the kidney, WNK–OSR1/SPAK signaling has been shown to be involved in the regulation of arterial tonus. In this context, the transporter involved is not NCC but NKCC1. *SPAK* knockout mice showed a decreased response to phenylephrine and decreased phosphorylation of NKCC1 (Yang et al., 2010). Similarly,

heterozygous *WNK1* knockout mice exhibited reduced phosphorylation of NKCC1 and reduced arterial tonus (Bergaya et al., 2011; Susa et al., 2012). Zeniya et al. (2013) reported the existence of WNK3–SPAK–NKCC1 signaling in vascular smooth muscle cells, which was regulated by salt intake through angiotensin II. Thus, WNK–OSR1/SPAK signaling is involved in the regulation of blood pressure by modulating both NaCl excretion in the kidney and vascular tonus in the arteries (Fig. 2).

In addition, mutation of the *WNK1* gene was shown to be responsible for human neuropathy (Shekarabi et al., 2008). WNK kinases were also shown to regulate KCl cotransporters (KCC family; Kahle et al., 2005; de de Los Heros et al., 2006; Garzon-Muvdi et al., 2007; Rinehart et al., 2009). The reciprocal regulation of NKCC1 and SLC12A5 (also known as KCC2) by WNK kinases is postulated to regulate intracellular chloride concentration, thereby regulating the excitability of neuronal cells (Kahle et al., 2006). Although data supporting this idea are accumulating, further validation by *in vivo* experiments is necessary.

Discovery of *Kelch-like 3* and *Cullin3* as pseudohypoaldosteronism type II causing genes

Although several upstream regulators of this cascade have been identified (Fig. 2), exactly how these regulators regulate WNK kinase activity remains largely unknown. Similarly, how PHAII-causing mutations of *WNK4* activate the cascade remained unelucidated. Recently, two new genes [*Kelch-like protein 3* (*KLHL3*) and *Cullin3*] were identified as genes responsible for causing PHAII (Boyden et al., 2012; Louis-Dit-Picard et al., 2012). However, how these genes were involved in causing PHAII was unknown. Determining how these genes (*WNKs*, *KLHL3* and *Cullin3*) interact and how their mutation causes a common hypertensive disease would contribute to the understanding of the molecular pathogenesis of human hypertension, and also to the identification of new targets for anti-hypertensive drugs.

KLHL3 is a member of the Kelch-like protein family, which consists of 42 members (Dhanoa et al., 2013). Kelch-like ECH-associated protein 1 (Keap1), known as the E3 ligase to NRF2, also belongs to the


KLHL family and is designated *KLHL19* (Dhanoa et al., 2013). In general, *KLHL* proteins contain one BTB domain, one BTB and C-terminal Kelch (BACK) domain, and five to six Kelch domains (Fig. 3). The BTB domain was named based on a homologous, 115-amino-acid domain present in *D. melanogaster* *bric a brac 1*, *tramtrack*, and *broad* complex proteins and facilitates the protein–protein interaction (Zollman et al., 1994). The Kelch domain forms one blade of a β -propeller structure, as shown in Fig. 3. This domain is also involved in the protein–protein interaction. Kelch domain-containing proteins have been shown to participate in many cellular functions, such as the regulation of cell morphology and gene expression (Adams et al., 2000). Mutations in *KLHL* genes reportedly cause multiple human diseases. *KLHL7* mutations cause autosomal dominant retinitis pigmentosa (Friedman et al., 2009; Kigoshi et al., 2011), and a missense mutation in *KLHL9* causes distal myopathy (Cirak et al., 2010). Mutations in *KLHL16* are linked to human giant axonal neuropathy (Bomont et al., 2000). In investigations of the molecular pathogenesis of these diseases, Kigoshi et al. (2011) clarified that *KLHL7* assembles with Cullin3 and exerts E3 ligase activity. Likewise, *KLHL20* was also reported to function as an E3 ligase in combination with Cullin3 on death-associated protein kinase (Lee et al., 2010), PDZ-Rho guanine nucleotide exchange factor (Lin et al., 2011) and promyelocytic leukemia protein (Yuan et al., 2011). *KLHL7* and *KLHL20* proteins bind to Cullin3 via their BTB domains and capture their substrates with their Kelch repeats. Therefore, it has been speculated that the *KLHL3*–Cullin3 complex also acts an E3 ligase on an unknown target protein.

WNK kinases are substrates of *Kelch-like protein 3*–*Cullin3* E3 ligase

As mutations in *WNK4*, *KLHL3* and *Cullin3* cause the same disease, PHAII, and the activation of WNK–OSR1/SPAK–NCC signaling underlies its pathogenesis, it is reasonable to speculate that components of this signaling cascade, in particular *WNK4*, could be the substrate of *KLHL3*–Cullin3 E3 ligase. A French group reported that *KLHL3* was able to bind to NCC and regulate its intracellular localisation (Louis-Dit-Picard et al., 2012). They did not investigate whether NCC was ubiquitinated by

Figure 3 | Structure of Kelch-like proteins

The upper panel shows the structure of Kelch-like (KLHL) proteins with N-terminal BTB and BACK domains and five to six C-terminal Kelch domains, and most autosomal dominant mutations causing pseudohypoaldosteronism type II (PHAII). The BTB domain is a binding site for Cullin 3 and Kelch repeats constitute a propeller structure, as shown in the lower panels, and capture a substrate. Each Kelch domain forms a blade, and most PHAII-causing mutations (shown in yellow lines) are located in the loop regions linking each blade, which may be involved in substrate binding.




KLHL3. Then, Ohta et al. (2013) and Wakabayashi et al. (2013) reported that WNK1 and WNK4 were substrates of KLHL3-Cullin3 E3 ligase, respectively. In both studies, the binding of KLHL3 to NCC was not reproduced. Subsequently, two further reports (Shibata et al., 2013; Wu and Peng, 2013) supported WNK4 as a target of KLHL3-Cullin3 E3 ligase.

Analyses of PHAII-causing mutations in *WNK4*, *KLHL3* and *Cullin 3* also clearly disclosed how these three proteins interact. As previously mentioned, PHAII-causing mutations in *WNK4* were clustered in the acidic domain, which is highly conserved in all WNK kinases (Fig. 1). Wakabayashi et al. (2013) and Mori et al. (2013) showed via fluorescent correlation spectroscopy that binding of KLHL3 to WNK4 was abolished by PHAII-causing mutations in *WNK4*, indicating that the acidic domain is involved in binding KLHL3. In contrast to WNK4, mutations in *KLHL3* were not confined to a single domain, but present in the BTB, BACK and Kelch domains. Mutations in the BTB and BACK domains affected the

ability of KLHL3 to bind Cullin3, whereas mutations in the Kelch domains affected the ability of KLHL3 to bind WNK1 and WNK4 (Mori et al., 2013). Impaired binding of KLHL3 to either Cullin3 or WNK4 decreased the ubiquitination of WNK4, resulting in increased WNK4 within cells. PHAII-causing *Cullin3* mutations are clustered around the splice donor and acceptor sites of exon 9. Boyden et al. (2012) showed via experiments in cultured cells that these mutations resulted in the skipping of exon 9. Osawa et al. (2013) and Tsuji et al. (2013) verified that exon 9 was skipped in the leukocytes of patients with PHAII. Mutant *Cullin3* lacking a portion of exon 9 did not show reduced binding to KLHL3, but E3 ligase activity towards WNK4 was significantly decreased (Wakabayashi et al., 2013). Thus, all PHAII-causing mutations in *WNK4*, *KLHL3* and *Cullin3* resulted in a common consequence: reduced ubiquitination of WNK4 and increased WNK4 protein within cells (Fig. 4). This increase in WNK4 protein was confirmed in the kidneys of *Wnk4*^{D561A/+} mice (Wakabayashi et al., 2013).

Figure 4 | Molecular pathogenesis of pseudohypoaldosteronism type II

Under normal conditions, WNK 4 protein within cells are maintained by appropriate degradation after ubiquitination by KLHL3-Cullin3 E3 ligase. However, PHAI1 causing-mutations in the acidic domain of WNK4 and in the Kelch domains of KLHL3 affect their binding, thereby reducing the ubiquitination and degradation of WNK4. PHAI1-causing mutant *Cullin3* lacking the portion corresponding to exon 9 exhibits lower E3 ligase activity in combination with KLHL3 toward WNK4. Thus, PHAI1-causing mutations in three different genes have a common consequence: decreased ubiquitination and increased WNK4 protein levels within cells. The increase in WNK4 protein was confirmed in the kidneys of *Wnk4*^{D561A/+} PHAI1 model mice. Furthermore, increased WNK4 protein levels in the kidneys of *WNK4* transgenic mice activated OSR1/SPAK–NCC signaling. Although WNK4 is the major WNK kinase regulating NCC in the kidney, other WNKs normally expressed at low levels could also be increased in kidneys with PHAI1 caused by *KLHL3* and *Cullin3* mutations, thereby contributing to the more severe phenotypes resulting from these mutations compared with those resulting from *WNK1* or *WNK4* mutations alone.



Increased WNK4 in kidney activates OSR1/SPAK–NCC signaling and causes PHAI1

Long-standing controversy exists about the influence of WNK4 on NCC function (McCormick and Ellison, 2011). Initially, WNK4 overexpression experiments in *X. laevis* oocytes showed that WNK4 is a negative regulator of NCC (Wilson et al., 2003; Yang et al. 2003). Further analyses by Yang et al. (2005, 2007b) showed that the inhibitory effect of WNK4 on NCC was not kinase activity dependent. Therefore, this inhibitory effect cannot be mediated by OSR1/SPAK–NCC signaling. Casteneda-Bueno et al. (2012) reported that *WNK4* knockout mice

exhibit a phenotype reminiscent of Gitelman syndrome (Gitelman syndrome is caused by the loss of function of NCC), indicating that WNK4 is a positive regulator of NCC *in vivo*. In fact, NCC phosphorylation, and even NCC protein abundance, was markedly decreased in the kidneys of *WNK4* knockout mice. Thus, it is barely possible that a decrease in WNK4 levels activate NCC, and there is little evidence that WNK4 is a negative regulator of NCC *in vivo*, except that *WNK4* BAC transgenic mice harboring a single copy of the wild-type *WNK4* transgene exhibited a Gitelman syndrome-like phenotype (Lalotot et al., 2006). The results of this transgenic mouse study were obtained through analysis of a single line